Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
The aim of the study was to determine the levels of selected cytokines and chemokines in the serum of multiple myeloma (MM) patients treated with bortezomib-based regimens. A total of 71 MM patients were examined: 41 with primary refractory disease (17) or early relapse (28), and 30 who were bortezo...
Saved in:
Main Authors: | Paweł Robak, Edyta Węgłowska, Izabela Dróżdż, Damian Mikulski, Dariusz Jarych, Magdalena Ferlińska, Ewa Wawrzyniak, Małgorzata Misiewicz, Piotr Smolewski, Wojciech Fendler, Janusz Szemraj, Tadeusz Robak |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2020/1835836 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment
by: Halina Urbanska-Rys, et al.
Published: (2003-01-01) -
Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus
by: Agnieszka Klonowska-Szymczyk, et al.
Published: (2014-01-01) -
Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro
by: Jolanta D. Żołnierczyk, et al.
Published: (2015-01-01) -
Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol
by: Vania dos Santos Nunes-Nogueira, et al.
Published: (2022-06-01) -
Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma
by: Jan Van Keer, et al.
Published: (2016-01-01)